{"id":"NCT01856543","sponsor":"Memorial Sloan Kettering Cancer Center","briefTitle":"Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation","officialTitle":"Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2017-01","completion":"2017-01","firstPosted":"2013-05-17","resultsPosted":"2019-10-03","lastUpdate":"2019-10-03"},"enrollment":143,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Invasive Breast Cancer"],"interventions":[{"type":"OTHER","name":"Eucerin","otherNames":[]},{"type":"OTHER","name":"Mometasone Furoate 0.1%","otherNames":[]}],"arms":[{"label":"Eucerin","type":"PLACEBO_COMPARATOR"},{"label":"Mometasone Furoate 0.1%","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to find out if the effect of mometasone furoate is any different from Eucerin in decreasing the severity of redness of the skin during irradiation, preventing the skin from peeling, or reducing the amount of irritation the patient reports during treatment.","primaryOutcome":{"measure":"Percentage of Participants With Moist Desquamation","timeFrame":"2 years","effectByArm":[{"arm":"Eucerin","deltaMin":66.7,"sd":null},{"arm":"Mometasone Furoate 0.1%","deltaMin":43.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mskcc.org/"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":73},"commonTop":["Lymphocyte count decreased","White blood cell decreased","Dermatitis radiation","Neutrophil count decreased","Anemia"]}}